Loading company…
Macrophage Pharma develops biopharmaceutical therapies that use the immune system to treat cancer and other complex diseases.
Its therapies are designed to enhance immune response, primarily for cancer, and are marketed to hospitals, healthcare providers and research institutions in North America and select European countries. Founded in 2014 in Windsor, UK, the company raised GBP 3.44 mn in Series A funding from M Ventures, valuing it at GBP 25.52 mn. CEO Søren Bregenholt leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in